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The pancreatic β cell harbors α2-adrenergic and glucagon-like peptide-1 (GLP-1) receptors on its plasma membrane to sense
the corresponding ligands adrenaline/noradrenaline and GLP-1 to govern glucose-stimulated insulin secretion. However, it is
not known whether these two signaling systems interact to gain the adequate and timely control of insulin release in response to
glucose.Thepresentworkshowsthattheα2-adrenergic agonistclonidineconcentration-dependentlydepresses glucose-stimulated
insulin secretion from INS-1 cells. On the contrary, GLP-1 concentration-dependently potentiates insulin secretory response
to glucose. Importantly, the present work reveals that subthreshold α2-adrenergic activation with clonidine counteracts GLP-1
potentiationofglucose-inducedinsulinsecretion.Thiscounteractoryprocessreliesonpertussistoxin-(PTX-)sensitiveGiproteins
sinceitnolongeroccurs followingPTX-mediated inactivationofGi proteins.Thecounteraction ofGLP-1potentiationofglucose-
stimulated insulin secretion by subthreshold α2-adrenergic activation is likely to serve as a molecular mechanism for the delicate
regulation of insulin release.
1.Introduction
Glucose-stimulated insulin secretion plays an irreplaceable
role in the control of glucose homeostasis since insulin is the
only hormone capable of lowering blood glucose in the body
[1–3]. This pancreatic endocrine hormone is packed in β
cell secretory granules. These granules undergo exocytosis to
release their insulin cargo into the bloodstream in response
to elevated blood glucose levels [1–3]. Upon elevation of the
plasma glucose level, the β cell eﬃciently takes up glucose
throughglucosetransporters. Thereafter, subsequentglucose
metabolism drastically raises the intracellular ATP level. The
resultant rise in the ATP/ADP ratio closes ATP-sensitive
K+ (KATP) channels, causing depolarization of the plasma
membrane. The membrane depolarization in turn opens
voltage-gated Ca2+ (CaV) channels, mediating Ca2+ inﬂux.
Theconsequentincreaseincytosolic-freeCa2+ concentration
([Ca2+]i) triggers direct interactions between exocytoticpro-
teins situated in the insulin-containing granule membrane
and those localized in the plasma membrane. Eventually, the
interactionbetweenexocytoticproteinsinitiatesthefusion of
insulin-containing granules with the plasma membrane, that
is, insulin exocytosis [1–3].
On top of the aforementioned consensus paradigm,
glucose-stimulated insulin secretion is, in fact, regulated
by complex neural mechanisms [4, 5]. It is well known
that the autonomic nervous system innervates pancreatic
islet cells where parasympathetic endings release a bunch of
substances, for example, acetylcholine and vasoactive intesti-
nal polypeptide, to potentiate glucose-stimulated insulin
secretion [5, 6]. On the contrary, sympathetic terminals
exocytose adrenergic and peptidergic transmitters to inhibit
the insulin secretory process [4, 5]. Treatment with the main
sympathetic transmitter noradrenaline fully shuts down
insulin secretion from either islets or β cell aggregates peri-
fused with high glucose[7,8].Mechanistically noradrenaline
acts on α2 receptors coupled to pertussis toxin- (PTX-)
sensitive Gi proteins in β cells, reducing glucose-stimulated2 Experimental Diabetes Research
insulin secretion through inhibition of intracellular cAMP
formation, CaV channels, glucose metabolism, and the
exocytotic machinery as well as elevation of KATP channel
activity [4, 5].
Glucose-stimulated insulin secretion is subjected not
only to the complex neural regulation, but also to various
diﬀerent types of hormonal regulation [9–16]. The islet β
cell is able to sense its own released molecules, such as zinc
and ATP, and hormones released from its neighboring cells
to autocrinally and paracrinally regulate insulin secretion
in response to glucose stimulation [13–18]. A number of
systemic hormones impinge on islet β cells to coordinate
insulin secretory response to glucose [9–12, 19]. A group of
gastrointestinal hormones has long attracted a great deal of
attention and categorized as incretins due to their stimula-
tory action on glucose-stimulated insulin secretion [9–12].
One of the most important incretin hormones is glucagon-
like peptide-1 (GLP-1), which is secreted from intestinal
L-cells into the bloodstream after a meal [9–12]. Upon
encounter with β cells, this incretin binds to Gs protein-
coupled receptors on these cells, resulting in activation of
adenylyl cyclases, CaV channels, glucose metabolism, and the
exocytotic machinery as well as inhibition of KATP channels
[9–12, 20–22]. As consequence of these events, potentiation
ofglucose-stimulatedinsulin secretion occurs[9–12, 20–22].
AlthougheithernoradrenergicorGLP-1signaling system
in the regulation of glucose-stimulated insulin secretion has
been clariﬁed, it is not known whether these two signaling
systems interact to gain adequate and timely insulin release
in response to glucose stimulation [4, 5, 9–12, 20–22]. In the
present work, we describe that subthreshold α2-adrenergic
activation counteracts glucagon-like peptide-1 potentiation
of glucose-stimulated insulin secretion in a PTX-sensitive Gi
protein-dependent manner.
2.Materialsand Methods
2.1. Cell Culture. INS-1 cells were cultivated in RPMI 1640
medium (Invitrogen, Carlsbad, CA) supplemented with
the following additives: 10% fetal bovine serum, 2mM
L-glutamine, and 100U/100μg/ml penicillin/streptomycin,
10mM N-[2-hydroxyethyl piperazine-N -2-ethanesulfonic
acid (HEPES), 1mM sodium pyruvate, and 50μM β-
mercaptoethanol (Invitrogen). Brieﬂy, the cells at about 70%
conﬂuency were trypsinized. The resultant cell suspension
was seeded into 24-well cell culture plates. The cells were
maintained at 37◦Ci nah u m i d i ﬁ e d5 %C O 2 incubator.
They were grown to approximately 70% conﬂuenceand then
subjected to analysis of insulin secretion.
2.2. Static Insulin Secretion. Approximately 70% conﬂuent
INS-1 cells in 24-well plates were used for insulin secretion
experiments. The cells were kept at 37◦Ci nah u m i d i ﬁ e d5 %
CO2 incubator during the course of an experiment except
when their bath solutions need to be changed. The experi-
ments were carried out in Krebs-Ringer bicarbonate HEPES
buﬀer (KRBH) consisting of (in mM) 140NaCl, 3.6KCl,
1.5CaCl2,0 . 5 M g S O 4,0 . 5 N a H 2PO4,2 N a H C O 3, 10HEPES,
0.1% bovine serum albumin (BSA), pH 7.4. First, the cells
were rinsed with glucose-free KRBH and then maintained
in the same buﬀer for 2h. Thereafter, they were rinsed
and preincubated with glucose-free KRBH for 30min. To
characterize the concentration-response relationships of the
α2-adrenergic agonist clonidine and the incretin GLP-1 as
well as interactions between noradrenergic and GLP-1 sig-
naling systems, the cells were rinsed and incubated with 3 or
11mM glucoseKRBHcontaining diﬀerentconcentrationsof
clonidine and/or GLP-1 for 30min. Clonidine and/or GLP-
1 were applied simultaneously with glucose. To determine a
possible dependence of α2-adrenoceptor regulation of GLP-
1 receptors on PTX-sensitive Gi proteins, the cells were
pretreated with 100ng/ml PTX in RPMI 1640 medium for
18h. Subsequently, the toxin medium was removed. The
cells were rinsed and incubated with glucose-free KRBH
as described above and subjected to incubations with 3 or
11mM glucoseKRBHcontaining diﬀerentconcentrationsof
clonidine and/or GLP-1 for 30min. Finally, the treatments
with the diﬀerent reagents were stopped by putting the
culture plates on ice. Supernatants were carefully aspirated
from each well to prepare samples for insulin quantiﬁcation.
The samples were centrifuged at 1000×gf o r3 m i nt o
remove detached cells and stored at −20◦C until insulin
immunoassay was performed.
2.3. Radioimmunoassay. A standard insulin immunoassay
was used to evaluate static insulin secretion from INS-
1 cells subjected to diﬀerent treatments [23, 24]. Brieﬂy,
duplicate samples were measured. The calibration curve was
constructed from insulin standard at 5, 10, 20, 40, 80, and
160mIU/L. Radioactivity was counted by a γ-counter.
2.4. Statistical Analysis. All data are presented as mean
± SEM. Statistical signiﬁcance was evaluated by one-way
ANOVA, followed by least signiﬁcant diﬀerence (LSD) test.
The signiﬁcance level was determined at both the 0.05 and
0.01 levels.
3.Results
3.1. Clonidine Concentration-Dependently Inhibits Glucose-
Stimulated Insulin Secretion. To determine the concentra-
tion response relationship of clonidine inhibition ofglucose-
stimulated insulin secretion, we examined the eﬀect of
30min incubation with clonidine at concentrations ranging
from 0.003 to 10μM on insulin release from INS-1 cells
challenged with 11mM glucose. As shown in Figure 1,
incubation with 11mM glucose for 30min resulted in a
signiﬁcant insulin secretion as compared with that with
3mM glucose (n = 6, P<. 01). This conﬁrms that the
cells used in this set of experiments reliably responded to
such stimulation to secrete an appreciableamount ofinsulin.
We therefore adopted this suﬃcient and reliable stimulation
to test for the eﬀect of clonidine on glucose-stimulated
insulin secretion. Figure 1 shows that in the concentration
range of 0.003–10μM, clonidine concentration-dependently
inhibited insulin release from INS-1 cells exposed to 11mMExperimental Diabetes Research 3
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Figure 1: The α2-adrenergic agonist clonidine concentration-
dependently depresses glucose-stimulated insulin secretion from
INS-1 cells. Static insulin secretion was performed with cells
subjected to stepwise elevation of glucose concentration from 3
to 11mM for 30min in the absence or presence of clonidine and
determined by a standard insulinradioimmunoassay.Cells exposed
to 11mM glucose (closed circle at the far left) released signiﬁcantly
more insulin than those to 3mM glucose (open circle) (n = 6,
P<. 01). In the concentration range of 0.003–10μM, clonidine
produced a concentration-dependent inhibition of insulin release
induced by 11mM glucose. The inhibition became statistically
signiﬁcantat0.01μMclonidine(n = 6,P<. 05)andwasstatistically
signiﬁcant at higher clonidine concentrations (n = 6, P<. 01). The
subthreshold and ED50 concentration of clonidine were calculated
to be 0.003 and 4μM, respectively. In this and all other ﬁgures, data
arepresented asmeans±SEM.Statisticalsigniﬁcancewasevaluated
by one-way ANOVA, followed by least signiﬁcant diﬀerence (LSD)
test. ∗P<. 05 and ∗∗P<. 01 versus 11mM glucose-treated group.
glucose. The eﬀect became statistically signiﬁcant when
clonidine concentration reached 0.01μMa n dh i g h e r( n =
6, P<. 05 at 0.01μM, P<. 01 at 0.1, 1 and 10μM).
The subthreshold and ED50 concentration of clonidine were
estimated to be 0.003 and 4μM, respectively.
3.2. Glucagon-Like Peptide-1 Concentration-Dependently
Stimulates Glucose-Stimulated Insulin Secretion. To
reveal the concentration-response relationship of GLP-
1 potentiation of glucose-stimulated insulin secretion, we
evaluated the insulin secretory response of INS-1 cells
stimulated with 11mM glucose for 30min in the presence
of GLP-1 in the concentration range 0.0001 to 1000nM.
Figure 2 shows that 11mM glucose treatment for 30min
produced a signiﬁcant increase in insulin secretion in
comparison with 3mM glucose treatment (n = 6, P<. 01).
This validates that the glucose responsiveness of the cells
employed in this set of experiments. As illustrated in
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Figure 2: The incretin GLP-1 concentration-dependently poten-
tiates glucose-stimulated insulin secretion from INS-1 cells. A
stepwise increase in glucose concentration from 3 to 11mM for
30min was used to induce static insulin secretion from cells
exposed to diﬀerent concentrations of GLP-1. Released insulin was
measured by a standard insulin radioimmunoassay.11mM glucose
incubation (closed circle at the far left) caused a signiﬁcant insulin
secretion from cells preincubated with 3mM glucose (n = 6,
P<. 01 versus 3mM glucose-treated group represented by an open
circle). GLP-1 at concentrations ranging from 0.0001 to 1000nM
potentiatedglucose-stimulatedinsulinsecretioninaconcentration-
dependent manner. GLP-1 at concentrations of 0.1nM and higher
signiﬁcantly enhanced insulin release from cells stimulated with
11mM glucose (n = 6, P<. 01 versus 11mM glucose-treated
group). The subthreshold and ED50 concentration of GLP-1 were
estimated to be 0.01 and 0.1nM, respectively. ∗∗P<. 01 versus
11mM glucose-treated group.
Figure 2, GLP-1 in the concentration range 0.0001 to
1000nM signiﬁcantly potentiated insulin release induced
by 11mM glucose in a concentration-dependent manner.
The statistically signiﬁcant potentiation occurred when
GLP-1 concentration was raised to 0.1nM and higher
(n = 6, P<. 01). A concentration of 0.01nM was
considered as the subthreshold concentration of GLP-1 on
its potentiation of glucose-stimulated insulin secretion. The
ED50 concentration of GLP-1 for potentiating the insulin
secretory response to glucose was calculated to be 0.1nM.
3.3. Subthreshold Clonidine Suppresses the Stimulatory
Eﬀect of Glucagon-Like Peptide-1 on Glucose-Stimulated
Insulin Secretion. The pancreatic β cell is equipped with
both the α2-adrenergic receptor and the GLP-1 recep-
tor which are impinged by the sympathetic transmitter
adrenaline/noradrenaline and the incretin hormone GLP-
1, respectively [4, 5, 9–12, 20–22]. Both of these systems
critically regulate glucose-stimulated insulin secretion [4, 5,
9–12, 20–22]. This inevitably raises the question whether
they are insulated from each other or one cross-talks with4 Experimental Diabetes Research
the other in pancreatic β cells. To tackle this issue, we
examined how subthreshold α2-adrenergic activation aﬀects
GLP-1 potentiation of glucose-stimulated insulin secretion.
Validation of the capacity of the cells applied in this set
of experiments to release insulin in response to glucose was
likewiseperformed. AsillustratedinFigure 3,tr eatmentwith
11mM glucose for 30min gave rise to a signiﬁcant insulin
release as compared with that with 3mM glucose (n = 10,
P<. 01). As expected, cells exposed to clonidine at the
subthreshold concentration 3nM did not alter their insulin
secretory response to 11mM glucose (n = 10, P>. 05
versus group subjected to only 11mM glucose stimulation)
(Figure 3). In contrast, cells treated with GLP-1 at the ED50
concentration 0.1nM following 11mM glucose stimulation
released signiﬁcantly more insulin than cells subjected to
only 11mM glucose stimulation (n = 10, P<. 05).
Importantly, cells incubated with the ED50 concentration
of GLP-1 plus the subthreshold concentration of clonidine
secreted signiﬁcantly less insulin than cells treated with the
ED50 concentrationofGLP-1 alone following 11mM glucose
stimulation (n = 10, P<. 01) (Figure 3). The insulin
secretory response to 11mM glucosewas very similar among
group treated with the ED50 concentration of GLP-1 plus
the subthreshold concentration of clonidine, group treated
with the subthreshold concentration of clonidine alone, and
untreated group (n = 10, P>. 05) (Figure 3). The data
demonstrate that the subthreshold concentration of cloni-
dine completely counteracted the potentiation of glucose-
stimulated insulin secretion by the ED50 concentration of
GLP-1.
3.4. Counteraction of Glucagon-Like Peptide-1 Potentiation of
Glucose-Stimulated Insulin Secretion by Clonidine Relies on
Pertussis Toxin-Sensitive Gi Proteins. Multiple intracellular
signaling events, such as decreases in cAMP production,
CaV channel activity, glucose metabolism, and exocytotic
capacity as well as an increase in KATP conductance occur
upon activation of α2-adrenergic receptors on the β cell to
depress glucose-stimulated insulin secretion [4, 5]. All these
events are dependent on the PTX-sensitive Gi protein that is
an immediate mediator for α2-adrenergic activation [4, 5].
This made uswonder if counteraction ofGLP-1 potentiation
of glucose-stimulated insulin secretion by clonidine relies
on PTX-sensitive Gi proteins. To circumvent this issue, we
evaluated if PTX-mediated inactivation of Gi proteins could
prevent counteraction of GLP-1 potentiation of glucose-
stimulated insulin secretion by subthreshold α2-adrenergic
activation.
The cells used in this set of experiments were proved
to be quite sensitive to glucose with regard to their insulin
secretory responsiveness. Figure 4 shows that both control
and PTX-pretreated cells released a signiﬁcant amount of
insulin when glucose concentration was raised from 3 to
11mM (n = 11, P<. 01). Cells pretreated with 100ng/ml
PTX in for 18h secreted signiﬁcantly more insulin than
cells without PTX pretreatment following 11mM glucose
stimulation (n = 11, P<. 01) (Figure 4). Clonidine at both
the subthreshold concentration 3nM and the ED50 concen-
tration 4μMh a dn oe ﬀect on insulin secretory response
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Figure 3: Subthreshold α2-adrenergic activation with clonidine
counteracts GLP-1potentiationofglucose-stimulatedinsulinsecre-
tion. A standard insulin radioimmunoassay was employed to
examine the insulin secretory response of cells treated with the
subthreshold concentration of clonidine, the ED50 concentration
of GLP-1 and their combinations following a stepwise stimulation
with glucose from 3 to 11mM for 30min. Treatment with 11mM
glucose caused a signiﬁcant insulin secretion as compared with
that with 3mM glucose (n = 10, P<. 01). Cells incubated with
clonidine at the subthreshold concentration 3nM and control cells
displayed similar insulin secretory responses to 11mM glucose
(n = 10, P>. 05). However, cells treated with GLP-1 at the
ED50 concentration 0.1nM displayed signiﬁcantlyenhanced insulin
secretion in comparison with untreated cells following 11mM
glucosestimulation(n = 10,P<. 05).Furthermore,cellsexposedto
the ED50 concentration of GLP-1 plus the subthreshold concentra-
tion of clonidine exhibited signiﬁcantly less insulin secretion than
cells treated with the ED50 concentration of GLP-1 alone following
11mM glucose stimulation (n = 10, P<. 01). Control cells and
cells treated either with the ED50 concentration of GLP-1 plus
the subthreshold concentration of clonidine or the subthreshold
concentrationofclonidinealonereleasedsimilaramountsofinsulin
in response to 11mM glucose (n = 10, P>. 05). ∗∗P<. 01
versus3mMglucose-treated group, +P<. 05versus11mMglucose-
treated group. ##P<. 01 versus the ED50 concentration of GLP-1
plus the subthreshold concentration of clonidine group subjected
to 11 mM glucose incubation.
to 11mM glucose in PTX-pretreated cells (n = 11, P>
.05 versus PTX-pretreated group subjected to only 11mM
glucose stimulation) (Figure 4). However, GLP-1 at the ED50
concentration 0.1nM signiﬁcantly enhanced insulin secre-
tion from PTX-pretreated cells following 11mM glucose
stimulation (n = 11, P<. 01 versus PTX-pretreated group
subjected to only 11mM glucose stimulation) (Figure 4).
Most importantly, the subthreshold concentration of cloni-
dine was unable to counteract potentiation of glucose-
stimulated insulin secretion by the ED50 concentration of
GLP-1 in PTX-pretreated cells (n = 11, P>. 05 versus PTX-
pretreated group treated with 11mM glucose plus 0.1nM
GLP-1) (Figure 4). The data reveal that counteraction of
GLP-1 potentiation of glucose-stimulated insulin secretion
by clonidine relies on PTX-sensitive Gi proteins.Experimental Diabetes Research 5
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Figure 4: Uncoupling of Gi proteins with PTX prevents counterac-
tion of GLP-1 potentiation of glucose-stimulated insulin secretion
by clonidine. Cells pretreated with 100ng/ml PTX for 18h and
control cells were subjected to analysis of static insulin secretion
induced by 11mM glucose for 30min in the absence or presence
of the subthreshold concentration and ED50 concentration of
clonidine, the ED50 concentration of GLP-1, and their combi-
nations. Insulin secretion was evaluated by a standard insulin
radioimmunoassay. Both control and PTX-pretreated cells well
responded to 30min stimulation with 11mM glucose (n = 11,
P<. 01 versus corresponding 3mM glucose-treated groups). PTX-
pretreated cells released signiﬁcantlymoreinsulin than controlcells
following 11mM glucose stimulation (n = 11, P<. 01). Neither
the subthreshold concentration (3nM) nor the ED50 concentration
(4μM) of clonidine altered glucose-stimulated insulin secretion in
PTX-pretreated cells (n = 11, P>. 05 versus PTX-pretreated group
subjected to only 11mM glucose stimulation). In contrast, GLP-1
at the ED50 concentration of 0.1nM induced a signiﬁcant potentia-
tion of glucose-induced insulin release from PTX-pretreated cells
(n = 11, P<. 01 versus PTX-pretreated group subjected to
only 11mM glucose stimulation). Intriguingly, glucose-stimulated
insulinsecretion fromPTX-pretreated cellsincubatedwiththeED50
concentration of GLP-1 alone did not signiﬁcantly diﬀer from that
from those subjected to incubation with the ED50 concentration
of GLP-1 plus the subthreshold concentration of clonidine (n =
11, P>. 05). Clonidine at the subthreshold concentration could
no longer inﬂuence potentiation of glucose-stimulated insulin
secretion by the ED50 concentration of GLP-1 in PTX-pretreated
cells. ∗∗P<. 01 versus 3mM glucose-treated group without PTX
pretreatment, ++P<. 01 versus 11mM glucose-treated group
without PTX pretreatment or PTX-pretreated group subjected to
3mMglucoseincubation,##P<. 01 versus PTX-pretreated group
subjected to 11mM glucose stimulation.
4.Discussion
Glucose homeostasis critically relies on the complex regu-
lation of glucose-stimulated insulin secretion by autonomic
impulsesand humoralinputstothepancreatic β cell [4, 5,9–
16]. α2-Adrenergic and GLP-1 receptors on the pancreatic
β cell transduce signals from their corresponding ligands
adrenaline/noradrenaline and GLP-1 to control glucose-
induced insulin release [4, 5, 9–12]. The present work
conﬁrms that the α2-adrenergic agonist clonidine and the
incretin GLP-1 concentration-dependently inhibits glucose-
induced insulin release at concentration ranges similar to
those employed in previous studies [8, 25, 26]. Furthermore,
it also estimates the subthreshold and ED50 concentration
of theses two agonists. These parameters are critical for
examination of the counteraction of GLP-1 potentiation
of glucose-stimulated insulin secretion by subthreshold α2-
adrenergic activation.
Most importantly, the present study shows for the ﬁrst
time that insulin-secreting INS-1 cells exposed to the ED50
concentration of GLP-1 together with the subthreshold
concentration of clonidine release signiﬁcantly less insulin
thancellstreatedwiththeED50 concentrationofGLP-1alone
following glucose stimulation. Furthermore, it also uncovers
that the antagonistic interaction of the α2-adrenergic signal-
ingsystemwiththeGLP-1signalingsystemcriticallydepends
on PTX-sensitive Gi proteins. These ﬁndings provide evi-
dence that α2-adrenergic or GLP-1 signaling system does
not operate independently, but instead the former eﬀectively
antagonizes the latter to enable the pancreatic β cell to
appropriately executeits uniquefunction glucose-stimulated
insulin secretion. In fact, interactions between G protein-
coupled receptor signaling pathways have been intensively
investigated in other cell types and neurons in particular
[27–33]. Such interactions rely on multilevel mechanisms
[27–33]. They occur at the receptor level due to receptor
heterodimerization, which is either G protein-dependent or
-independent [27–30]. The heterodimerization is able to
alter the ligand binding aﬃnity and/or signal transduction
eﬃcacy of dimerized receptors [27–30, 32, 33]. Interactions
between G protein-coupled receptor signaling pathways can
also bypass the receptor level and come about downstream
of receptors as a result of crosstalk between receptor
signaling cascades [31]. In general, these well-characterized
mechanisms are applicable to the counteraction of GLP-
1 potentiation of glucose-stimulated insulin secretion by
subthreshold α2-adrenergic activation in the pancreatic β
cell. The in-depth mechanisms whereby the α2-adrenergic
signaling system antagonizes the GLP-1 signaling system in
the pancreatic β cell remain to be characterized.
There is no doubt that the healthy body requires the
eﬃcient amount of insulin to remove extra glucose from
the blood stream into body cells most of the time. However,
the healthy body needs less insulin to boost blood glucose
levels in some circumstances, such as stress, exercise, low
blood glucose, and other environmental challenges. The
counteraction of GLP-1 potentiation of glucose-stimulated
insulin secretion by subthreshold α2-adrenergic activation
deﬁnitely ﬁts in with these circumstances where sympathetic
activity is elevated [34]. It adds a new level of complexity to
the classical paradigm for the regulation of glucose-evoked
insulin release. Under certain pathological conditions, for
example, diabetes, hypertension, obesity, and aging, sympa-
thetic activity and/or expression of α2-adrenergic receptors
in the β cell signiﬁcantly increase [35–39]. Increases in
sympathetic activity and/or expression of α2-adrenergic
receptors in the β cell likely exaggerate the antagonistic6 Experimental Diabetes Research
interaction of the α2-adrenergic signaling system with the
GLP-1 signaling system in the pancreatic β cell to provoke
and aggravate diabetes [35–39].
5.Conclusions
α2-Adrenergic receptors and GLP-1 receptors on insulin-
secreting INS-1 cells transduce signals from their corre-
sponding ligands clonidine and GLP-1 to govern glucose-
induced insulin release. Importantly, the former also inter-
acts with the latter to brake potentiation of glucose-
induced insulin release by the latter. In fact, subthreshold
α2-adrenergic activation is enough to counteract GLP-1
potentiation of glucose-induced insulin secretion in a PTX-
sensitiveGiprotein-dependentfashion.Suchacounteraction
is able to serve as a molecular mechanism for the delicate
control of insulin release in the healthy body. Most likely,
this counteractory process is exaggerated to provoke and
aggravate diabetes since obesity, aging, and diabetes are
highly associated with elevated sympathetic activity [35–39].
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